Xilio Therapeutics GAAP EPS of -$0.30 beats by $0.64, revenue of $9.98M beats by $5.06M
at seekingalpha.com (Tue, 10-Nov 9:24 AM)
Xilio doses first patient in XTX501 Phase 1/2 trial, setting a Q4 2027 data milestone in metastatic NSCLC
Market Chameleon (Mon, 26-Oct 11:21 AM)
